📉 Nikkei is down nearly 5% -> here are 43 recession-proof Japanese stocks from our screenerUnlock Now

Element 25 and car giant Stellantis extend key offtake and funding dates

Published 01/05/2023, 12:47 pm
Updated 01/05/2023, 01:00 pm
© Reuters.  Element 25 and car giant Stellantis extend key offtake and funding dates

Element 25 Ltd (ASX:E25) has extended key days in its funding and offtake agreement with car giant Stellantis.

The companies signed the offtake and project financing agreement on January 25 this year, for the supply of battery-grade high-purity, manganese sulphate monohydrate (HPMSM) from E25’s proposed US-based processing facility.

The agreement combines take or pay offtake commitments for 45Kt of HPMSM from the facility over five years with US$30 million in two tranches of project funding towards the facility capital cost. Tranche 1 of the funding comprises a US$15 million equity investment in E25.

E25 managing director Justin Brown sat down with Proactive’s Elisha Newell at the time to discuss the pivotal agreement with the global carmaker, calling it “a fantastic endorsement from one of the world’s largest automakers”.

Today, E25 and Stellantis which is behind such brands as Chrysler, Maseratti, Citroen, Fiat, RAM, Opel and Dodge among others, agreed to extend the cut off date for conditions precedent to the Agreement (CPs) which were originally set to expire on April 30, 2023.

Understanding the conditions

While several of the conditions have soi far been met, some need extra time to be worked out.

The CPs for the overall transaction between E25 and Stellantis include:

  • Stellantis completing a technical due diligence process to its satisfaction. [NOW COMPLETED]
  • A decision by the E25 board to proceed with the project based on the feasibility study (FS). [NOW COMPLETED]
  • E25 completing a successful HPMSM FS for a USA-based HPMSM facility to Stellantis’ reasonable satisfaction.
  • CP for the Share Subscription Agreement and Offtake Agreement – by April 30 2023.
  • E25 securing a minimum of US$100 million project financing.
Further to these precedents, the agreement also provides for Stellantis to have 20 days to review the FS prior to accepting it in satisfaction of E25 completing a successful HPMSM FS for a USA-based HPMSM facility to Stellantis’ reasonable satisfaction.

The original expiry date would not have provided the allocated 20 days for this review and has now been extended to May 15, 2023.

The expiry dates for all CPs listed above is now June 30, 2023, which the companies believe will provide sufficient time for the FS review and for the satisfaction of the remaining CPs to allow for the first tranche of $15 million project funding to be completed.

Read more on Proactive Investors AU

Disclaimer

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.